A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors by de Braud, Filippo et al.
Annals of Oncology 26: 2341–2346, 2015
doi:10.1093/annonc/mdv354
Published online 22 September 2015
A phase I, dose-escalation study of volasertib combined
with nintedanib in advanced solid tumors
F. de Braud1*,†, S. Cascinu2, G. Spitaleri3, K. Pilz4,‡, L. Clementi5, D. Liu4, P. Sikken4 & T. De Pas3
1Director of New Drug Development Unit, European Institute of Oncology, Milan; 2Department of Medical Oncology, Polytechnic University of the Marche Region, Ancona;
3Medical Oncology Unit of Respiratory Tract and Sarcomas, Division of New Drugs Development, European Institute of Oncology, Milan, Italy; 4Boehringer Ingelheim
Pharma GmbH & Co. KG, Biberach, Germany; 5Boehringer Ingelheim Italia S.p.A., Milan, Italy
Received 23 December 2014; revised 27 May 2015 and 31 July 2015; accepted 5 August 2015
Background: Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by
targeting Polo-like kinases. This study determined the maximum tolerated dose (MTD) and pharmacokinetics of volasertib
combined with nintedanib, a potent and orally bioavailable triple angiokinase inhibitor, in patients with advanced solid
tumors.
Patients and methods: This open-label, dose-escalation trial recruited patients with advanced metastatic solid tumors
following failure of conventional treatment (NCT01022853; Study 1230.7). Volasertib was administered by intravenous
infusion over 2 h, starting at 100 mg in the first dose cohort. Nintedanib was administered orally at a dose of 200 mg
twice daily. The first treatment cycle comprised 28 days (days 1–7 and days 9–28: nintedanib; day 8: volasertib). From
cycle 2 onwards, volasertib was administered on day 1 of a 21-day cycle and nintedanib was administered days 2–21.
The primary objective was the MTD of volasertib in combination with nintedanib.
Results: Thirty patients were treated. The MTD of volasertib plus fixed-dose nintedanib was 300 mg once every 3
weeks, the same as the recommended single-agent dose of volasertib in solid tumors. Two of 12 assessable patients
treated with the MTD experienced dose-limiting toxicities [grade 3 increased alanine aminotransferase (ALT); grade 3 ALT
increase and grade 3 increased aspartate aminotransferase]. Disease control [stable disease (SD)/partial response
(PR)/complete response (CR)] was achieved in 18 patients (60%): 1 CR (breast cancer), 1 PR (nonsmall-cell lung cancer),
and 16 patients with SD. Volasertib showed that multiexponential pharmacokinetic behavior and co-administration of
nintedanib had no significant effects on its exposure.
Conclusions: Volasertib could be combined with fixed-dose nintedanib at the recommended single-agent dose. At this
dose, the combination had a manageable safety profile without unexpected or overlapping adverse events, and showed
antitumor activity.
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introduction
Members of the Polo-like kinase (Plk) family are key regulators
of cell mitosis [1]. Plk1, the best characterized family member,
is known to regulate various mitotic processes [2]. Various
human tumors overexpress Plk1 [3] and its functional relevance
in cancer was shown in experiments in which Plk1 depletion
reduced cell proliferation and induced cell-cycle arrest and
apoptosis in cancer cell lines [4, 5]. Volasertib is a highly
potent and selective inhibitor of Plk that inhibits proliferation
and induces mitotic arrest and apoptosis [6]. The efficacy of
volasertib has been demonstrated in various tumor models [6],
and phase I trials in solid tumors have shown favorable pharma-
cokinetics and manageable toxicity [7, 8]. Disease control rates
of 45% [including three partial responses (PR) in 65 assessable
patients] [8] and 47% (including two PRs in 59 assessable
patients) [7] were observed.
Proangiogenic factors such as platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF), and basic
fibroblast growth factor (bFGF) have been implicated in tumor
angiogenesis [9], a process essential for invasive growth and me-
tastasis [10]. Nintedanib is a potent and orally bioavailable triple
angiokinase inhibitor of PDGF, VEGF, and bFGF receptors [11].
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In addition, nintedanib inhibits FLT3, RET, and members of the
Src family. Clinical trials of nintedanib have demonstrated antitu-
mor activity and a generally manageable safety profile as a mono-
therapy in patients with various solid tumors and in combination
with cytotoxic chemotherapy in two phase III studies in advanced
nonsmall-cell lung cancer (NSCLC) [12, 13] and a phase III study
in advanced ovarian cancer [14]. One complete response (CR)
and two PRs were observed with nintedanib monotherapy in a
phase I trial [15].
Combined administration of multiple drugs, an approach
long adopted with traditional anticancer agents, is now under
evaluation with targeted therapies [16]. This strategy is based on
the hypothesis that combination therapy using agents with dif-
ferent mechanisms of action, such as an antimitotic (volasertib)
and an angiokinase inhibitor (nintedanib), would be more
effective than single-agent therapy. Here we report the first clin-
ical trial designed to determine the maximum tolerated dose
(MTD), safety, and pharmacokinetics of volasertib combined
with fixed-dose nintedanib in patients with advanced solid
tumors resistant or refractory to standard therapy.
patients andmethods
patients
Eligible patients had a confirmed diagnosis of advanced, metastatic solid
tumors following failure of conventional treatment, for whom no therapy of
proven efficacy existed or who were not amenable to established forms of
treatment. Full eligibility criteria are provided in supplementary Patients and
Methods, available at Annals of Oncology online. All patients provided
written informed consent.
study design
This was an open-label, phase I, dose-escalation trial, conducted at two sites
in Italy between January 2010 and February 2013 (EudraCT number: 2008-
008304-41; ClinicalTrials.gov identifier: NCT01022853; Study 1230.7).
Cohorts of patients were sequentially allocated to different volasertib doses.
Volasertib was administered once every 3 weeks (q3w) by intravenous infu-
sion over 2 h, starting at 100 mg in the first cohort and escalated in four
dose steps (200, 300, 350, and 400 mg). Nintedanib was administered orally
at a dose of 200 mg twice daily (b.i.d.) on non-volasertib infusion days. This
nintedanib dose is currently being evaluated in phase III trials and was
selected based on the findings of phase I/II studies [15, 17, 18]. Nintedanib
treatment was started 7 days before treatment with volasertib to induce
nintedanib steady-state levels at the time of first volasertib administration.
Administration of nintedanib was skipped on the days that volasertib was
administered based on the schedule of nintedanib combined with other
agents in phase III trials [12, 13]. The first cycle comprised 28 days: days 1–7
and 9–28, nintedanib b.i.d.; day 8, volasertib. From cycle 2 onwards, volaser-
tib was administered on day 1 of a 21-day cycle and nintedanib was adminis-
tered b.i.d. days 2–21. Dose escalation of volasertib followed a traditional
‘3 + 3’ design. An expansion cohort of additional patients treated at the
MTD was planned to provide additional safety data. A dose-reduction
scheme allowed for treatment modification in case of a prespecified adverse
event (AE) or dose-limiting toxicity (DLT). If the treatment was tolerable,
patients received additional therapy cycles until clinical progression.
study objectives
The primary objective was the MTD of volasertib q3w combined with con-
tinuous nintedanib 200 mg b.i.d. Secondary objectives were: incidence and
intensity of drug-related AEs; incidence of DLTs; pharmacokinetics of vola-
sertib and nintedanib; tumor response, and progression-free survival (PFS).
assessments
MTD and DLTs. MTD was defined as the highest dose at which no
more than one of six patients experienced a DLT during or after volasertib
administration between days 8 and 21 of the first cycle. The replacement
criteria for patients non-assessable for the MTD analysis are listed in
supplementary Patients and Methods, available at Annals of Oncology
online. DLTs were defined as: drug-related Common Terminology Criteria
for Adverse Events (CTCAE) grade 3/4 nonhematologic AEs (except
untreated vomiting, nausea, or diarrhea); drug-related CTCAE grade 4
neutropenia for ≥7 days and/or complicated by infection; and CTCAE grade
4 thrombocytopenia. All DLTs during all treatment cycles were considered
when selecting a volasertib dose to be used for further development in
combination with nintedanib.
safety. All AEs that occurred during treatment or within 28 days after last
administration of study medication were recorded. AE incidence and
intensity were graded according to National Cancer Institute (NCI) CTCAE
v3.0 [19]. AEs were classified according to relationship to study medication;
however, no systematic attribution of AEs to either volasertib or nintedanib
was carried out. Other safety measures are listed in supplementary Patients
and Methods, available at Annals of Oncology online.
pharmacokinetics. Plasma concentrations of volasertib and its major
metabolite CD 10899 were obtained on days 8 (before and after volasertib
infusion), 9, 10, 15, and 22 of the first treatment cycle (11 time points), and
on day 1 of the second cycle. Plasma concentrations of nintedanib were
obtained on days 8, 9, and 10 of the first treatment cycle and on day 1 of the
second cycle. Samples were analyzed by validated high-performance liquid
chromatography, tandem mass spectrometry assay in the laboratory of
Boehringer Ingelheim Pharma GmbH & Co. KG (Biberach, Germany).
efficacy. Clinical tumor assessment was carried out at baseline and after
every other treatment cycle using Response Evaluation Criteria in Solid
Tumors (RECIST) v1.1 [20]. Time from start of treatment to time of
progression or death (PFS) was determined for each patient.
statistics
Patients who were replaced during the first treatment course were not con-
sidered for determination of the MTD. All treated patients were included in
the safety and efficacy analysis. All evaluable subjects who received at least
one dose of volasertib and nintedanib and provided at least one valid plasma
concentration value were included in the pharmacokinetic (PK) analysis.
SAS® v9.2 (SAS Institute, Inc., Cary, NC, USA) was used for all statistical
analyses. Details of statistical analyses, including sample size calculation and
reasons for replacement of patients, are provided in supplementary Patients
and Methods, available at Annals of Oncology online.
results
patients
Forty-three patients were enrolled and 30 patients were treated
(see supplementary Results for Patient Disposition, available
at Annals of Oncology online). Median age was 56.5 years (Table 1).
Most patients (60%) had Eastern Cooperative Oncology Group per-
formance status (ECOG PS) 1; 87% had received ≥3 prior che-
motherapies. The most common tumor type was colorectal cancer
(33%). All patients presented with metastases. Median (range)
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duration on treatment was four (1–18) cycles. Treatment was dis-
continued due to progressive disease (80%), DLTs (3%), or other
reasons (17%).
determination of maximum tolerated dose
No DLTs were observed in the 100 mg (n = 3), 200 mg (n = 4;
one patient was non-assessable due to an incorrect nintedanib
dose in week 1 of cycle 1), 300 mg (n = 3), and 350 mg cohorts
(n = 4; one patient was non-assessable as laboratory examina-
tions were not carried out per protocol). Two patients were
treated with 400 mg volasertib and both experienced DLTs
[grade 4 thrombocytopenia (duration: 11 days), n = 1; grade 4
thrombocytopenia (21 days) and grade 4 febrile neutropenia
(3 days), n = 1]. Four additional patients then enrolled to the de-
escalated dose of 350 mg volasertib (one patient did not receive
volasertib and was non-assessable). Of the three assessable
patients, two experienced DLTs [grade 4 neutropenia (15 days)
and grade 4 thrombocytopenia (17 days), n = 1; grade 4 neutro-
penia (9 days) and grade 3 alanine aminotransferase (ALT) in-
crease (15 days), n = 1]. As the number of acceptable DLTs was
exceeded again at 350 mg (2/6), three additional patients were
treated with de-escalated 300 mg volasertib without experien-
cing DLTs. As no DLTs occurred in the six patients treated with
300 mg during the dose-escalation period, the MTD of volaser-
tib combined with nintedanib was established as 300 mg.
Another seven patients were treated with 300 mg volasertib in
an extension cohort, of which six were assessable (one was
excluded as a result of a protocol violation due to receiving gran-
ulocyte-colony stimulating factor for nonlife-threatening grade
4 neutropenia); two experienced DLTs during the first course
[grade 3 ALT increase (11 days), n = 1; grade 3 ALT increase
and grade 3 aspartate aminotransferase (AST) increase (7 days
each), n = 1]. Therefore, the overall incidence of DLTs in the
300 mg cohort occurring during the first treatment course was 2
of 12 patients and the MTD was confirmed as 300 mg.
safety
Over all cycles, drug-related AEs were reported in 90% of
patients (Table 2) and serious AEs occurred in 27%. Overall,
47% of patients experienced AEs that led to a reduction in either
the volasertib and/or nintedanib dose, and 17% experienced
AEs that led to discontinuation [due to progression of cancer,
hematological abnormalities (neutropenia, thrombocytopenia),
and hypertension in the volasertib 300 mg group (n = 2); pro-
gression of cancer in the 350 mg group (n = 1); and hematologic
abnormalities (febrile neutropenia, leukopenia, neutropenia,
thrombocytopenia) and dyspnea in the 400 mg group (n = 1)].
Drug-related AEs reported in ≥6 patients (20%) are listed in
supplementary Table S1, available at Annals of Oncology online.
Of 13 patients treated with the MTD (300 mg; includes 1 patient
non-assessable for MTD determination), the most common all
grade, drug-related AEs were neutropenia (69%), diarrhea and
thrombocytopenia (62% each), and increased ALT and AST
(54% each). The most common grade 3/4 drug-related AEs were
neutropenia (50%), thrombocytopenia (30%), increased ALT
(23%), and increased AST (17%). Two patients died during
treatment (one each in the 300 and 350 mg cohorts); both
Table 1. Patient demographics and disease characteristics
Nintedanib 200 mg + volasertib All patients (N = 30)
100 mg (N = 3) 200 mg (N = 4) 300 mg (N = 13) 350 mg (N = 8) 400 mg (N = 2)
Median age, years (min, max) 51.0 (45, 63) 57.5 (55, 70) 57.0 (40, 74) 52.5 (33, 69) 59.0 (55, 63) 56.5 (33, 74)
Male/female, n (%) 2/1 (67/33) 3/1 (75/25) 6/7 (46/54) 6/2 (75/25) 1/1 (50/50) 18/12 (60/40)
ECOG performance status, n (%)
0 0 2 (50) 5 (39) 2 (25) 1 (50) 10 (33)
1 3 (100) 2 (50) 7 (54) 5 (63) 1 (50) 18 (60)
2 0 0 1 (8) 1 (13) 0 2 (7)
Metastases at screening, n (%) 3 (100) 4 (100) 13 (100) 8 (100) 2 (100) 30 (100)
Tumor type, n (%)
Head/neck 0 0 2 (15) 0 0 2 (7)
NSCLC 0 1 (25) 3 (23) 1 (13) 0 5 (17)
Mediastinum 0 0 2 (15) 2 (25) 0 4 (13)
Colorectal 1 (33) 2 (50) 3 (23) 2 (25) 2 (100) 10 (33)
Kidney 0 1 (25) 0 1 (13) 0 2 (7)
Breast 0 0 2 (15) 0 0 2 (7)
Othera 2 (67) 0 1 (8) 2 (25) 0 5 (17)
Previous anticancer therapy, n (%)
Surgery 3 (100) 4 (100) 12 (92) 6 (75) 2 (100) 27 (90)
Chemotherapy 3 (100) 4 (100) 13 (100) 8 (100) 2 (100) 30 (100)
2 lines 2 (67) 1 (25) 0 1 (13) 0 4 (13)
≥3 lines 1 (33) 3 (75) 13 (100) 7 (88) 2 (100) 26 (87)
Radiotherapy 3 (100) 2 (50) 4 (31) 6 (75) 0 15 (50)
Some groups may add up to more or less than 100% due to rounding of percentages.
aIncludes soft tissue sarcoma, pancreas, bladder, urethra/penis, and pleura (n = 1 for each tumor type).
ECOG, Eastern Cooperative Oncology Group; NSCLC, nonsmall-cell lung cancer.
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deaths were due to progressive disease and were not considered
drug-related.
Laboratory examinations reflected the AE profile such that
most patients with possibly clinically significant abnormalities
had transaminase elevations and/or changes in hematologic
parameters. No clinically meaningful changes in vital signs or
ECOG PS status were reported. Electrocardiogram analyses
showed transient Fridericia corrected QT interval (QTcF), Bazett
corrected QT interval, and QT prolongations which peaked at or
shortly after the end of the volasertib infusion and returned to
baseline levels within 24 h. An outlier analysis identified one
patient with a notable finding (QT interval >500 ms at 2-h time
point); the patient’s QT interval recovered immediately at the
next measured time point.
pharmacokinetics
Volasertib exhibited multiexponential PK behavior with fast dis-
tribution after the end of infusion, followed by slower elimination
phases; the major metabolite CD 10899 showed similar PK be-
havior (supplementary Figure S3, available at Annals of Oncology
online). Volasertib had a long half-life (124−143 h), a moderate
clearance (685−849 ml/min), and a large volume of distribution
(>5000 l); there were no significant deviations from dose propor-
tionality with respect to the maximum plasma concentration or
area under the concentration–time curve (Table 3). CD 10899
exposure was ∼16%–21% of the volasertib exposure (Table 3).
Maximum plasma concentrations of nintedanib occurred
within 2−3 h after oral administration, steady-state plasma
concentration was achieved after 7 days of continuous oral ad-
ministration of 200 mg b.i.d. Per protocol, nintedanib 200 mg b.
i.d. was not administered on the day of the volasertib infusion;
nintedanib steady state was achieved again 1 day after the restart
of its administration and maintained for the rest of the treat-
ment course. The shape of the nintedanib concentration time
profiles were similar across cohorts, although exposure to ninte-
danib increased as volasertib dose increased (see supplementary
Table 2. Summary of adverse events
Nintedanib 200 mg + volasertib All patients
(N = 30)100 mg
(N = 3)
200 mg
(N = 4)
300 mg
(N = 13)
350 mg
(N = 8)
400 mg
(N = 2)
Any AE, n (%) 3 (100) 4 (100) 13 (100) 8 (100) 2 (100) 30 (100)
Maximum CTCAE grade
1 0 0 1 (8) 0 0 1 (3)
2 3 (100) 1 (25) 0 1 (13) 0 5 (17)
3 0 3 (75) 9 (69) 4 (50) 0 16 (53)
4 0 0 2 (15) 2 (25) 2 (100) 6 (20)
5 0 0 1 (8) 1 (13) 0 2 (7)
Any drug-related AE, n (%) 3 (100) 3 (75) 12 (92) 7 (88) 2 (100) 27 (90)
Any AE leading to discontinuation of study
medication, n (%)
0 0 2 (15) 1 (13) 2 (100) 5 (17)
Any AE leading to reduction of study medication
dose, n (%)
0 1 (25) 8 (62) 4 (50) 1 (50) 14 (47)
Any SAE, n (%) 0 0 5 (39) 2 (25) 1 (50) 8 (27)
Some groups may add up to more or <100% due to rounding of percentages.
AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events (v3.0); SAE, serious adverse event.
Table 3. Noncompartmental pharmacokinetic parameters of volasertib (100–350 mg) after 2 h intravenous infusion on day 8 of cycle 1
Pharmacokinetic parameter, volasertib gMean (gCV%) Volasertib + nintedanib 200 mg
100 mg (N = 3) 200 mg (N = 4) 300 mg (N = 12) 350 mg (N = 6)
Cmax,norm (ng/ml) 1.64 (77.6) 2.05 (23.3) 1.77 (33.3) 1.52 (25.5)
AUC0–504,norm (ng·h/ml/mg) 21.9 (20.3) 23.0 (3.77) 19.9 (33.5) 20.6 (33.9)
CL (ml/min) 720 (19.3) 685 (4.22) 792 (34.2) 849 (29.3)
Vss (l) 5710 (39.9) 5590 (6.53) 5010 (34.7) 6080 (21.2)
t1/2 (h) 143 (10.9) 142 (12.2) 124 (27.3) 127 (26.2)
RAUC0–∞,CD10899/volasertib 21.3 (19.5) 16.4 (39.2) 16.8 (45.9) 17.6 (31.4)
Evaluations were carried out using WinNonlin™ Professional (Pharsight® Co., v5.2) software.
AUC0–504,norm, dose-normalized area under the plasma concentration–time curve from time 0 to 504 h; CL, total plasma clearance; Cmax,norm, dose-
normalized maximum plasma concentration; gCV, geometric coefficient of variance; gMean, geometric mean; RAUC0–∞,CD10899/volasertib, ratio of the area
under the plasma concentration–time curve from time zero to infinity (metabolite/volasertib); t1/2, terminal half-life; Vss, volume of distribution at steady
state.
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Table S2, available at Annals of Oncology online, for nintedanib
PK parameters).
efficacy
A best overall response of CR was observed in one patient
(moderately differentiated ductal infiltrating breast carcinoma)
and a PR was observed in one patient with NSCLC (broncheo-
loalveolar adenocarcinoma with KRAS mutation) [see supple-
mentary Figure S1, available at Annals of Oncology online, for
computerized tomography (CT) scans]. Both patients received
300 mg volasertib plus nintedanib and had PFS of 447 and 267
days, respectively. Stable disease (SD) was reported in an
additional 16 patients. Disease control (SD/PR/CR) was observed
in 18 patients (60%) with a median duration of 161.5 days (range,
56–512 days). The duration of disease control is shown in supple-
mentary Figure S2, available at Annals of Oncology online.
discussion
This first clinical study of volasertib in combination with ninteda-
nib demonstrates that this combination was generally well
tolerated by patients with advanced solid malignancies resistant or
refractory to standard therapy. The MTD of volasertib combined
with 200 mg nintedanib b.i.d. was established as 300 mg volasertib
q3w, the same dose recommended for single-agent treatment of
solid tumors [8]. The incidence of hematological DLTs at volaser-
tib doses >300 mg was consistent with comparable phase I dose-
escalation studies [7, 8]. Transaminase elevations are known AEs
with nintedanib; however, phase I/II studies suggested a dose
threshold of >200 mg nintedanib b.i.d. for increased incidences of
transaminase elevations. In this study, the incidences of trans-
aminase elevations classified as DLTs at 200 mg nintedanib b.i.d.
indicated a greater impact by the addition of volasertib.
Observed hematologic AEs are consistent with the actions of
volasertib on the cell cycle and with previous studies [7, 8].
Overall reported AEs of the combination were consistent with
the known safety profiles of both volasertib and nintedanib.
Antitumor activity was observed with two patients achieving
an objective response with treatment at the MTD and SD was
observed in a total of 16 patients across all dose cohorts. The
disease control rate was 60.0% and seven patients maintained
disease control ≥6 months. The disease control rate observed
in this study is higher than in comparable volasertib phase I
dose-escalation studies [7, 8] and consistent with similar phase I
trials investigating angiogenetic inhibitors in combination with
chemotherapy in patients with solid tumors [21, 22]. These
studies contribute to our understanding of oncogenesis and
support Plk and angiogenesis as valid therapeutic targets in cancer.
Given the phase I design, this study is of limited value in defining
the patient population that would benefit from this combination in
future clinical studies. However, given the wide antitumor activity
(response or significant disease stabilization) observed in this
heavily pretreated patient population, further clinical investigation
of combination volasertib and nintedanib is warranted.
Systemic exposure and PK characteristics of volasertib and
CD 10899 were similar to those observed in earlier studies of
volasertib monotherapy in solid tumors [7, 8], suggesting that
nintedanib has no influence on the PK characteristics and
metabolism of volasertib. The PK concentration–time profile of
nintedanib was also similar to that observed in previous studies
with nintedanib monotherapy [15, 18]. Given the large variabil-
ity in exposure, it can be suggested that the exposure to the nin-
tedanib metabolites BIBF 1202 and BIBF 1202-glucuronide was
similar across volasertib dose cohorts, and co-administration of
volasertib did not appear to affect nintedanib metabolism.
However, slight increases in nintedanib exposure were observed
as the dose of volasertib was increased. As volasertib is an
inhibitor of the efflux transporter P-glycoprotein (P-gp) and
nintedanib is a P-gp substrate, this effect may be explained by
the inhibitory effect of volasertib on the P-gp-mediated efflux in
the gut following oral administration of nintedanib. In general,
however, the individual variability of the PK data for nintedanib
and its metabolites was high and, therefore, the data regarding
the influence of volasertib on nintedanib pharmacokinetics and
metabolism should be interpreted with caution.
In conclusion, this study established that, in patients with solid
tumors, volasertib can be combined with fixed-dose nintedanib
at the recommended single-agent dose of volasertib. At this dose,
the safety profile of combination treatment is manageable and in
line with the known safety profiles of the individual drugs and
the combination may be feasible in patients with solid tumors
based on the very good compliance and the long-lasting disease
stabilization observed in this study. The identification of biomar-
kers predictive of response will be critical for the further develop-
ment of this therapy in patients with advanced solid tumors.
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